# US 2024/0197877 A1 · Binding proteins recognizing ha-2 antigen and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197877 A1
- Document ID: US20240197877A1
- Status: Published application
- Kind: A1
- Application number: 18/286,726
- Filed: 2022-04-14
- Published: 2024-06-20
- Earliest claimed: 2021-04-14
- Assignees: TScan Therapeutics, Inc.
- Applicants: TScan Therapeutics, Inc.
- Inventors: Ribhu Nayar; Gavin MacBeath; Sonal Jangalwe; Mollie M. Jurewicz; Andrew S. Basinski; Qikai Xu; Antoine J. Boudot; Tomasz Kula
- Web page: https://patentgrep.com/patent/US20240197877A1

## CPC

- A61P 31/12: Antivirals
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/70517: {CD8}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C07K 16/18: against material from animals or humans
- C12N 5/0636: {T lymphocytes}
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/41: containing a Myc-tag
- C07K 2319/42: containing a HA(hemagglutinin)-tag
- C07K 2319/43: containing a FLAG-tag
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/231: Interleukin-10 (IL-10)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2502/11: blood or immune system cells
- C12N 2502/30: tumour cells
- C12N 2502/99: genetically modified cells
- C12N 2510/00: Genetically modified cells
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are binding proteins recognizing HA-2 antigen and uses thereof.

## Claims

### Claim 1

A binding protein comprising:
a) a T cell receptor (TCR) alpha chain CDR sequence with at least about 80% identity to a TCR alpha chain CDR sequence selected from the group consisting of TCR alpha chain CDR sequences listed in Table 1; and/or
b) a TCR beta chain CDR sequence with at least about 80% identity to a TCR beta chain CDR sequence selected from the group consisting of TCR beta chain CDR sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.

### Claim 2

A binding protein comprising:
a) a TCR alpha chain variable (Vα) domain sequence with at least about 80% identity to a TCR Vα domain sequence selected from the group consisting of TCR Vα domain sequences listed in Table 1; and/or
b) a TCR beta chain variable (Vβ) domain sequence with at least about 80% identity to a TCR Vβ domain sequence selected from the group consisting of TCR Vβ domain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.

### Claim 3

A binding protein comprising:
a) a TCR alpha chain sequence with at least about 80% identity to a TCR alpha chain sequence selected from the group consisting of TCR alpha chain sequences listed in Table 1; and/or
b) a TCR beta chain sequence with at least about 80% identity to a TCR beta chain sequence selected from the group consisting of TCR beta chain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.

### Claim 4

A binding protein comprising:
a) a TCR alpha chain CDR sequence selected from the group consisting of TCR alpha chain CDR sequences listed in Table 1; and/or
b) a TCR beta chain CDR sequence selected from the group consisting of TCR beta chain CDR sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.

### Claim 5

A binding protein comprising:
a) a TCR alpha chain variable (Vα) domain sequence selected from the group consisting of TCR Vα domain sequences listed in Table 1; and/or
b) a TCR beta chain variable (Vβ) domain sequence selected from the group consisting of TCR Vβ domain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.

### Claim 6

A binding protein comprising:
a) a TCR alpha chain sequence selected from the group consisting of TCR alpha chain sequences listed in Table 1; and/or
b) a TCR beta chain sequence selected from the group consisting of TCR beta chain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The binding protein of any one of claims 1-6, wherein 1) the TCR alpha chain CDR, TCR Vα domain, and/or TCR alpha chain is encoded by a TRAV, TRAJ, and/or TRAC gene or fragment thereof selected from the group of TRAV, TRAJ, and TRAC genes listed in Table 1, and/or 2) the TCR beta chain CDR, TCR Vβ domain, and/or TCR beta chain is encoded by a TRBV, TRBJ, and/or TRBC gene or fragment thereof selected from the group of TRBV, TRBJ, and TRBC genes listed in Table 1, and/or 3) each CDR of the binding protein has up to five amino acid substitutions, insertions, deletions, or a combination thereof as compared to the cognate reference CDR sequence listed in Table 1.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The binding protein of any one of claims 1-7, wherein the HA-2 immunogenic peptide comprises the amino acid sequence YIGEVLVSV or YIGEVLVSM.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The binding protein of any one of claims 1-8, wherein the binding protein is chimeric, humanized, or human.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The binding protein of any one of claims 1-9, wherein the binding protein is a TCR, an antigen-binding fragment of a TCR, a single chain TCR (scTCR), a chimeric antigen receptor (CAR), or a fusion protein comprising a TCR and an effector domain, optionally wherein the binding domain comprises a transmembrane domain and an effector domain that is intracellular.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The binding protein of any one of claims 1-10, wherein the TCR alpha chain and the TCR beta chain are covalently linked, optionally wherein the TCR alpha chain and the TCR beta chain are covalently linked through a linker peptide.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The binding protein of any one of claims 1-11, wherein the TCR alpha chain and/or the TCR beta chain are covalently linked to a moiety, optionally wherein the covalently linked moiety comprises an affinity tag or a label.

### Claim 13 (depends on 12)

The binding protein of claim 12, wherein the affinity tag is selected from the group consisting of CD34 enrichment tag, Glutathione-S-Transferase (GST), calmodulin binding protein (CBP), protein C tag, Myc tag, HaloTag, HA tag, Flag tag, His tag, biotin tag, and V5 tag, and/or wherein the label is a fluorescent protein.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The binding protein of any one of claims 1-13, wherein the covalently linked moiety is selected from the group consisting of an inflammatory agent, cytokine, toxin, cytotoxic molecule, radioactive isotope, or antibody or antigen-binding fragment thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The binding protein of any one of claims 1-14, wherein the binding protein binds to the pMHC complex on a cell surface.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The binding protein of any one of claims 1-15, wherein the MHC is a MHC multimer, optionally wherein the MHC multimer is a tetramer.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The binding protein of any one of claims 1-16, wherein the MHC is a MHC class I molecule.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The binding protein of any one of claims 1-17, wherein the MHC comprises an MHC alpha chain that is an HLA serotype HLA-A*02.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The binding protein of any one of claims 1-18, wherein the HLA allele is selected from the group consisting of HLA-A*0201, HLA-A*0202, HLA-A*0203, HLA-A*0205, HLA-A*0206, and HLA-A*0207 allele.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The binding protein of any one of claims 1-19, wherein binding of the binding protein to the HA-2 peptide-MHC (pMHC) complex elicits an immune response, optionally wherein the immune response is a T cell response.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The binding protein of any one of claims 1-20, wherein the T cell response is selected from the group consisting of T cell expansion, cytokine release, and/or cytotoxic killing.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The binding protein of any one of claims 1-21, the binding protein is capable of specifically binding to the HA-2 immunogenic peptide-MHC (pMHC) complex with a Kd less than or equal to about 1×10−4 M, less than or equal to about 5×10−5 M, less than or equal to about 1×10−5 M, less than or equal to about 5×10−6 M, less than or equal to about 1×10−6 M, less than or equal to about 5×10−7 M, less than or equal to about 1×10−7 M, less than or equal to about 5×10−8 M, less than or equal to about 1×10−8 M, less than or equal to about 5×10−9 M, less than or equal to about 1×10−9 M, less than or equal to about 5×10−10 M, less than or equal to about 1×10−10 M, less than or equal to about 5×10−11 M, less than or equal to about 1×10−11 M, less than or equal to about 5×10−12 M, or less than or equal to about 1×10−12 M.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The binding protein of any one of claims 1-22, wherein the binding protein has a higher binding affinity to the peptide-MHC (pMHC) than does a known T-cell receptor.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The binding protein of any one of claims 1-23, wherein the binding protein has at least 1.05-fold higher binding affinity to the peptide-MHC (pMHC) than does a known T-cell receptor.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The binding protein of any one of claims 1-24, wherein the binding protein induces higher T cell expansion, cytokine release, and/or cytotoxic killing than does a known T-cell receptor when contacted with target cells with a heterozygous expression of HA-2.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The binding protein of any one of claims 1-25, wherein the binding protein induces at least 1.05-fold increase in T cell expansion, cytokine release, and/or cytotoxic killing than does a known T-cell receptor when contacted with target cells with a heterozygous expression of HA-2.

### Claim 27 (depends on 25, 26)

The binding protein of claim 25 or 26, wherein the target cell is a DEL, THP-1, or TF-1 cell line.

### Claim 28 (depends on 25, 26)

The binding protein of claim 25 or 26, wherein the target cell is a cancer cell.

### Claim 29 (depends on 28)

The binding protein of claim 28, wherein the cancer is a hematological malignancy.

### Claim 30 (depends on 29)

The binding protein of claim 29, wherein the hematological malignancy is a leukemia, a lymphoma, a myelodysplastic disorder, a myeloproliferative neoplasm, or a myeloma.

### Claim 31

A TCR alpha chain and/or beta chain selected from the group consisting of TCR alpha chain and beta chain sequences listed in Table 1.

### Claim 32

An isolated nucleic acid molecule that hybridizes, under stringent conditions, with the complement of a nucleic acid encoding a polypeptide selected from the group consisting of polypeptide sequences listed in Table 1, or a sequence with at least about 80% homology to a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptide sequences listed in Table 1, optionally wherein the isolated nucleic acid molecule comprises 1) a TRAV, TRAJ, and/or TRAC gene or fragment thereof selected from the group of TRAV, TRAJ, and TRAC genes listed in Table 1 and/or 2) a TRBV, TRBJ, and/or TRBC gene or fragment thereof selected from the group of TRBV, TRBJ, and TRBC genes listed in Table 1.

### Claim 33 (depends on 32)

The isolated nucleic acid of claim of claim 32, wherein the nucleic acid is codon optimized for expression in a host cell.

### Claim 34 (depends on 32, 33)

A vector comprising the isolated nucleic acid of claim 32 or 33.

### Claim 35 (depends on 34)

The vector of claim 34, wherein the vector is a cloning vector, expression vector, or viral vector.

### Claim 36 (depends on 34, 35)

The vector of claim 34 or 35, wherein the vector further comprises nucleic acid sequence encoding CD8α and/or CD8β.

### Claim 37 (depends on 34, 35, 36)

The vector of any one of claims 34-36, wherein the nucleic acid sequence encoding CD8α or CD8β is operably linked to a nucleic acid encoding a tag.

### Claim 38 (depends on 34, 35, 36, 37)

The vector of any one of claims 34-37, wherein the nucleic acid encoding a tag is at the 5′ upstream of the nucleic acid sequence encoding CD8α or CD8β such that the tag is fused to the N-terminus of CD8α or CD8β.

### Claim 39 (depends on 34, 35, 36, 37, 38)

The vector of any one of claims 34-38, wherein the tag is a CD34 enrichment tag.

### Claim 40 (depends on 23, 24, 34, 35, 36, 37, 38, 39)

The vector of any one of claims 34-39, wherein the isolated nucleic acid of claim 23 or 24, and the nucleic acid sequence encoding CD8α and/or CD8β are interconnected with an internal ribosome entry site or a nucleic acid sequence encoding a self-cleaving peptide.

### Claim 41 (depends on 34, 35, 36, 37, 38, 39, 40)

The vector of any one of claims 34-40, wherein the self-cleaving peptide is β2A, E2A, F2A or T2A.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A host cell which comprises the isolated nucleic acid of claim 32 or 33, comprises the vector of any one of claims 34-41, and/or expresses the binding protein of any one of claims 1-30, optionally wherein the cell is genetically engineered.

### Claim 43 (depends on 42)

The host cell of claim 42, wherein the host cell comprises a chromosomal gene knockout of a TCR gene, an HLA gene, or both.

### Claim 44 (depends on 42, 43)

The host cell of claim 42 or 43, wherein the host cell comprises a knockout of an HLA gene selected from an α1 macroglobulin gene, α2 macroglobulin gene, α3 macroglobulin gene, β1 microglobulin gene, β2 microglobulin gene, and combinations thereof.

### Claim 45 (depends on 42, 43, 44)

The host cell of any one of claims 42-44, wherein the host cell comprises a knockout of a TCR gene selected from a TCR α variable region gene, TCR β variable region gene, TCR constant region gene, and combinations thereof.

### Claim 46 (depends on 42, 43, 44, 45)

The host cell of any one claims 42-45, wherein the host cell expresses CD8α and/or CD8β.

### Claim 47 (depends on 46)

The host cell of claim 46, wherein the CD8α and/or CD8β is fused to a CD34 enrichment tag.

### Claim 48 (depends on 47)

The host cell of claim 47, wherein host cells are enriched using the CD34 enrichment tag.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The host cell of any one of claims 42-48, wherein the host cell is a hematopoietic progenitor cell, peripheral blood mononuclear cell (PBMC), cord blood cell, or immune cell.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The host cell of any one of claims 42-49, wherein the immune cell is a cytotoxic lymphocyte, cytotoxic lymphocyte precursor cell, cytotoxic lymphocyte progenitor cell, cytotoxic lymphocyte stem cell, CD4+ T cell, CD8+ T cell, CD4/CD8 double negative T cell, gamma delta (γδ) T cell, natural killer (NK) cell, NK-T cell, dendritic cell, or combination thereof.

### Claim 51 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50)

The host cell of any one of claims 42-50, wherein the T cell is a naïve T cell, central memory T cell, effector memory T cell, or a combination thereof.

### Claim 52 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The host cell of any one of claims 42-51, wherein the T cell is a primary T cell or a cell of a T cell line.

### Claim 53 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The host cell of any one of claims 42-52, wherein the T cell does not express or has a lower surface expression of an endogenous TCR.

### Claim 54 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The host cell of any one of claims 42-53, wherein the host cell is capable of producing a cytokine or a cytotoxic molecule when contacted with a target cell that comprises a peptide-MHC (pMHC) complex comprising the HA-2 peptide epitope in the context of an MHC molecule.

### Claim 55 (depends on 54)

The host cell of claim 54, wherein the host cell is contacted with the target cell in vitro, ex vivo, or in vivo.

### Claim 56 (depends on 54, 55)

The host cell of claim 54 or 55, wherein the cytokine is TNF-α, IL-2, and/or IFN-γ.

### Claim 57 (depends on 54, 55, 56)

The host cell of any one of claims 54-56, wherein the cytotoxic molecule is perforins and/or granzymes, optionally wherein the cytotoxic molecule is granzyme B.

### Claim 58 (depends on 54, 55, 56, 57)

The host cell of any one of claims 54-57, wherein the host cell is capable of producing a higher level of cytokine or a cytotoxic molecule when contacted with a target cell with a heterozygous expression of HA-2.

### Claim 59 (depends on 58)

The host cell of claim 58, wherein the host cell is capable of producing an at least 1.05-fold higher level of cytokine or a cytotoxic molecule.

### Claim 60 (depends on 54, 55, 56, 57, 58, 59)

The host cell of any one of claims 54-59, wherein the host cell is capable of killing a target cell that comprises a peptide-MHC (pMHC) complex comprising the HA-2 peptide epitope in the context of an MHC molecule.

### Claim 61 (depends on 60)

The host cell of claim 60, wherein the killing is determined by a killing assay.

### Claim 62 (depends on 60, 61)

The host cell of claim 60 or 61, wherein the ratio of the host cell and the target cell in the killing assay is from 20:1 to 0.625:1.

### Claim 63 (depends on 60, 61, 62)

The host cell of any one of claims 60-62, wherein a target cell is a T2 cell pulsed with 1 μg/mL to 50 μg/mL of HA-2 peptide.

### Claim 64 (depends on 60, 61, 62)

The host cell of any one of claims 60-62, wherein the host cell is capable of killing a higher number of target cells when contacted with target cells with a heterozygous expression of HA-2.

### Claim 65 (depends on 64)

The host cell of claim 64, wherein the host cell is capable of killing an at least 1.05-fold higher number of target cells.

### Claim 66 (depends on 60, 61, 64, 65)

The host cell of any one of claims 60, 61, 64 and 65, wherein the target cell is a DEL, THP-1, or TF-1 cell line.

### Claim 67 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The host cell of any one of claims 54-66, wherein the HA-2 immunogenic peptide comprises the amino acid sequence YIGEVLVSV or YIGEVLVSM.

### Claim 68 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The host cell of any one of claims 54-67, wherein the MHC molecule is a MHC class I molecule.

### Claim 69 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The host cell of any one of claims 54-68, wherein the MHC molecule comprises an MHC alpha chain that is an HLA serotype HLA-A*02.

### Claim 70 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The host cell of any one of claims 54-69, wherein the HLA allele is selected from the group consisting of HLA-A*02:01, HLA-A*0202, HLA-A*0203, HLA-A*0205, HLA-A*0206, and HLA-A*0207 allele.

### Claim 71 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The host cell of any one of claims 54-70, wherein the target cell is a cell line selected from the group consisting of Del, THP-1, and TF-1 cell lines, is a hematopoietic cancer cell expressing HA-2, or is not NB4.

### Claim 72 (depends on 71)

The host cell of claim 71, wherein the cancer cell is of a hematological malignancy selected from the group consisting of a leukemia, a lymphoma, a myelodysplastic disorder, a myeloproliferative neoplasm, or myeloma.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The host cell of any one of claims 54-71, wherein the host cell does not express HA-2 antigen, is not recognized by a binding protein of any one of claims 1-30, is not of serotype HLA-A*02, and/or does not express an HLA-A*02 allele.

### Claim 74 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A population of host cells of any one of claims 42-73.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A composition comprising: a) a binding protein according to any one of claims 1-30, b) an isolated nucleic acid according to claim 32 or 33, c) a vector according to any one of claims 34-41, d) a host cell according to any one of claims 42-73, and/or e) a population of host cells according to claim 74, and a carrier.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A device or kit comprising: a) a binding protein according to any one of claims 1-30, b) an isolated nucleic acid according to claim 32 or 33, c) a vector according to any one of claims 34-41, d) a host cell according to any one of claims 42-73, and/or e) a population of host cells according to claim 74, said device or kit optionally comprising a reagent to detect binding of a), d) and/or e) to a pMHC complex.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A method of producing a binding protein according to any one of claims 1-30, wherein the method comprises the steps of: (i) culturing a transformed host cell which has been transformed by a nucleic acid comprising a sequence encoding a binding protein according to any one of claims 1-30 under conditions suitable to allow expression of said binding protein; and (ii) recovering the expressed binding protein.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A method of producing a host cell expressing a binding protein according to any one of claims 1-30, wherein the method comprises the steps of: (i) introducing a nucleic acid comprising a sequence encoding a binding protein according to any one of claims 1-30 into the host cell; (ii) culturing the transformed host cell under conditions suitable to allow expression of said binding protein.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A method of detecting the presence or absence of an HA-2 antigen and/or a cell expressing HA-2, optionally wherein the cell is a hyperproliferative cell, comprising detecting the presence or absence of said HA-2 antigen in a sample by use of at least one binding protein according to any one of claims 1-30, or at least one host cell according to any one of claims 42-73, wherein detection of the HA-2 antigen is indicative of the presence of an HA-2 antigen and/or cell expressing HA-2.

### Claim 80 (depends on 79)

The method of claim 79, wherein the at least one binding protein, or the at least one host cell, forms a complex with the HA-2 peptide in the context of an MHC molecule, and the complex is detected in the form of fluorescence activated cell sorting (FACS), enzyme linked immunosorbent assay (ELISA), radioimmune assay (RIA), immunochemically, Western blot, or intracellular flow assay.

### Claim 81 (depends on 79, 80)

The method of claim 79 or 80, further comprising obtaining the sample from a subject.

### Claim 82 (depends on 79, 80, 81)

The method of any one of claims 79-81, further comprising confirming cells expressing HA-2 by bone marrow biopsy.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A method of detecting the level of a non-malignant disorder, a hyperproliferative disorder, or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in a subject, comprising:
a) contacting a sample obtained from the subject with at least one binding protein according to any one of claims 1-30, at least one host cell according to any one of claims 42-73, or a population of host cells according to claim 74; and
b) detecting the level of reactivity,
wherein a higher level of reactivity compared to a control level indicates the level of a non-malignant disorder, a hyperproliferative disorder, or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in the subject.

### Claim 84 (depends on 83)

The method of claim 83, wherein the control level is a reference number.

### Claim 85 (depends on 83)

The method of claim 83, wherein the control level is a level of a subject without the non-malignant disorder, a hyperproliferative disorder, or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen.

### Claim 86 (depends on 79, 80, 81, 82, 83, 84, 85)

A method for monitoring the progression of a non-malignant disorder, a hyperproliferative disorder, or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in a subject, the method comprising:
a) detecting in a subject sample at a first point in time the level of the HA-2 antigen or the cell of interest expressing HA-2, according to any one of claims 79-85;
b) repeating step a) at a subsequent point in time; and
c) comparing the level of the HA-2 antigen or the cell of interest expressing HA-2 detected in steps a) and b) to monitor the progression of a non-malignant disorder, a hyperproliferative disorder, or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in the subject, wherein an absent or reduced level of the HA-2 antigen or the cell of interest expressing HA-2 detected in step b) compared to step a) indicates an inhibited progression of the non-malignant disorder, the hyperproliferative disorder, or the relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in the subject.

### Claim 87 (depends on 86)

The method of claim 86, wherein between the first point in time and the subsequent point in time, the subject has undergone treatment to treat the non-malignant disorder, the hyperproliferative disorder, or the relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A method of assessing the efficacy of a therapy for a non-malignant disorder, a hyperproliferative disorder, or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen comprising:
a) determining the presence or level of reactivity between a sample obtained from a subject and at least one binding protein according to any one of claims 1-30, at least one host cell according to any one of claims 42-73, or a population of host cells according to claim 74, in a first sample obtained from the subject prior to providing at least a portion of the therapy for the non-malignant disorder, the hyperproliferative disorder, or the relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen to the subject, and
b) determining the presence or level of reactivity between a sample obtained from the subject and at least one binding protein according to any one of claims 1-30, at least one host cell according to any one of claims 42-73, or a population of host cells according to claim 74, in a second sample obtained from the subject following provision of the portion of the therapy for the non-malignant disorder, the hyperproliferative disorder, or the relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen,
wherein the absence or a reduced level of reactivity in the second sample, relative to the first sample, is an indication that the therapy is efficacious for treating the non-malignant disorder, the hyperproliferative disorder, or the relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in the subject.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The method of any one of claims 83-88, wherein the level of reactivity is indicated by a) the presence of binding and/or b) T cell activation and/or effector function, optionally wherein the T cell activation or effector function is T cell proliferation, killing, or cytokine release.

### Claim 90 (depends on 89)

The method of claim 89, wherein the T cell activation or effector function is T cell proliferation, killing, or cytokine release.

### Claim 91 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

The method of any one of claims 83-90, wherein the T cell binding, activation, and/or effector function is detected using fluorescence activated cell sorting (FACS), enzyme linked immunosorbent assay (ELISA), radioimmune assay (RIA), immunochemically, Western blot, or intracellular flow assay.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A method of preventing and/or treating a non-malignant disorder, a hyperproliferative disorder or a relapse of a hyperproliferative disorder characterized by expression of an HA-2 antigen in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising cells expressing at least one binding protein of any one of claims 1-30.

### Claim 93 (depends on 92)

The method of claim 92, wherein the cell is an allogeneic cell, syngeneic cell, or autologous cell.

### Claim 94 (depends on 92, 93)

The method of claim 92 or 93, wherein the cell is genetically modified.

### Claim 95 (depends on 92, 93, 94)

The method of any one of claims 92-94, wherein the cell comprises a chromosomal gene knockout of a TCR gene, an HLA gene, or both a TCR gene and an HLA gene.

### Claim 96 (depends on 92, 93, 94, 95)

The method of any one of claims 92-95, wherein the cell comprises a knockout of an HLA gene selected from an α1 macroglobulin gene, α2 macroglobulin gene, α3 macroglobulin gene, β1 microglobulin gene, β2 microglobulin gene, and a combination thereof.

### Claim 97 (depends on 92, 93, 94, 95, 96)

The method of any one of claims 92-96, wherein the cell comprises a knockout of a TCR gene selected from a TCR α variable region gene, TCR β variable region gene, TCR constant region gene, and combinations thereof.

### Claim 98 (depends on 92, 93, 94, 95, 96, 97)

The method of any one claims 92-97, wherein the cell expresses CD8α and/or CD8β,
optionally wherein the CD8α and/or CD8β is fused to a CD34 enrichment tag.

### Claim 99 (depends on 98)

The method of claim 98, wherein cells are enriched using the CD34 enrichment tag.

### Claim 100 (depends on 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 92-99, wherein the cell is a hematopoeitic progenitor cell, peripheral blood mononuclear cell (PBMC), cord blood cell, or immune cell.

### Claim 101 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100)

The method of any one of claims 92-100, wherein the immune cell is a cytotoxic lymphocyte, cytotoxic lymphocyte precursor cell, cytotoxic lymphocyte progenitor cell, cytotoxic lymphocyte stem cell, CD4+ T cell, CD8+ T cell, CD4/CD8 double negative T cell, gamma delta (γδ) T cell, natural killer (NK) cell, NK-T cell, dendritic cell, or combination thereof.

### Claim 102 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 92-101, wherein the T cell is a naive T cell, central memory T cell, effector memory T cell, or combination thereof.

### Claim 103 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The method of any one of claims 92-102, wherein the T cell is a primary T cell or a cell of a T cell line.

### Claim 104 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The method of any one of claims 92-103, wherein the T cell does not express or has a lower surface expression of an endogenous TCR.

### Claim 105 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The method of any one of claims 92-104, wherein the cell is capable of producing a cytokine or a cytotoxic molecule when contacted with a target cell that comprises a peptide-MHC (pMHC) complex comprising the HA-2 in the context of an MHC molecule.

### Claim 106 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The method of any one of claims 92-105, wherein the cytokine is TNF-α, IL-2, and/or IFN-γ.

### Claim 107 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The method of any one of claims 92-106, wherein the cytotoxic molecule is perforins and/or granzymes, optionally wherein the cytotoxic molecule is granzyme B.

### Claim 108 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method of any one of claims 92-107, wherein the cell is capable of producing a higher level of cytokine or a cytotoxic molecule when contacted with a target cell with a heterozygous expression of HA-2.

### Claim 109 (depends on 108)

The method of claim 108, wherein the cell is capable of producing an at least 1.05-fold higher level of cytokine or a cytotoxic molecule.

### Claim 110 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The method of any one of claims 92-109, wherein the host cell is capable of killing a target cell that comprises a peptide-MHC (pMHC) complex comprising an HA-2 in the context of an MHC molecule.

### Claim 111 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The method of any one of claims 92-110, wherein the host cell is capable of killing a higher number of target cells when contacted with target cells with a heterozygous expression of HA-2.

### Claim 112 (depends on 111)

The method of claim 111, wherein the host cell is capable of killing an at least 1.05-fold higher number of target cells.

### Claim 113 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The method of any one of claims 92-112, wherein the HA-2 immunogenic peptide comprises the amino acid sequence YIGEVLVSV or YIGEVLVSM.

### Claim 114 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The method of any one of claims 92-113, wherein the MHC molecule is an MHC class I molecule.

### Claim 115 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any one of claims 92-114, wherein the MHC molecule comprises an MHC alpha chain that is an HLA serotype HLA-A*02.

### Claim 116 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The method of any one of claims 92-115, wherein the HLA allele is selected from the group consisting of HLA-A*02:01, HLA-A*0202, HLA-A*0203, HLA-A*0205, HLA-A*0206, and HLA-A*0207 allele.

### Claim 117 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The method of any one of claims 92-116, wherein the target cell is a non-malignant cell or a hyperproliferating cell expressing the HA-2 antigen in the subject.

### Claim 118 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The method of any one of claims 92-117, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 119 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 92-118, wherein the composition induces an immune response against the non-malignant cells or the hyperproliferating cells expressing the HA-2 antigen in the subject.

### Claim 120 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The method of any one of claims 92-119, wherein the composition induces an antigen-specific T cell immune response against the non-malignant cells or the hyperproliferating cells expressing the HA-2 antigen in the subject.

### Claim 121 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The method of any one of claims 92-120, wherein the antigen-specific T cell immune response comprises at least one of a CD4+ helper T lymphocyte (Th) response and a CD8+ cytotoxic T lymphocyte (CTL) response.

### Claim 122 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any one of claims 83-121, wherein the hyperproliferative disorder comprises a hematological malignancy.

### Claim 123 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

The method of any one of claims 83-122, wherein the hematological malignancy comprises a leukemia, a lymphoma, a myelodysplastic disorder, a myeloproliferative neoplasm, or a myeloma.

### Claim 124 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The method of any one of claims 83-123, wherein the hematological malignancy comprises a leukemia.

### Claim 125 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The method of any one of claims 83-124, wherein the leukemia is selected from acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), mixed phenotype acute leukemia (MPAL), chronic myeloid leukemia (CML), B cell prolymphocytic leukemia, hairy cell leukemia, or chronic lymphocytic leukemia (CLL).

### Claim 126 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The method of any one of claims 83-125, wherein the hematological disorder comprises a lymphoma.

### Claim 127 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The method of any one of claims 83-125, wherein the lymphoma is selected from Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), a central nervous system lymphoma, small lymphocytic lymphoma (SLL), CD37+ dendritic cell lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extra-nodal marginal zone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, precursor B-lymphoblastic lymphoma, immunoblastic large cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, or Burkitt's lymphoma.

### Claim 128 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The method of any one of claims 83-123, wherein the hematological malignancy comprises a myelodysplastic disorder (MDS), optionally wherein the MDS is selected from refractory cytopenia with unilineage dysplasia (refractory anemia, refractory neutropenia, and refractory thrombocytopenia), refractory anemia with ring sideroblasts (RARS), refractory anemia with ring sideroblasts-thrombocytosis (RARS-t), refractory cytopenia with multinieage dysplasia (RCMD), refractory cytopenia with multinieage dysplasia and ring sideroblasts (RCMD-RS), refractory anemia with excess blasts (RAEB), myelodysplasia unclassifiable, refractory cytopenia of childhood, or MDS with isolated del(5q).

### Claim 129 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The method of any one of claims 83-123, wherein the non-malignant disorder is an immune deficiency disorder, optionally wherein the immune deficiency disorder is selected from the group consisting of severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, Omenn syndrome, X-linked lymphoproliferative syndrome, chronic granulomatous disease, leukocyte adhesion deficiency, DiGeorge syndrome, and indications for hematopoietic stem cell transplantation (HCT).

### Claim 130 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any one of claims 83-121, wherein the non-malignant disorder is a non-malignant hematology disorder, optionally wherein the non-malignant hematology disorder is selected from the group consisting of sickle cell anemia, thalassemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), severe aplastic anemia, marrow failure syndromes, Fanconi anemia, Diamond-Blackfan anemia, and Shwachman Diamond syndrome.

### Claim 131 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any one of claims 83-121, wherein the non-malignant disorder is an autoimmune disorder, optionally wherein the autoimmune disorder is systemic sclerosis or multiple sclerosis.

### Claim 132 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The method of any one of claims 92-131, wherein the subject is receiving or previously received a hematopoietic cell transplant (HCT), optionally wherein the HCT comprises cells that do not express HA-2 antigen, are not recognized by a binding protein of any one of claims 1-30, are not of serotype HLA-A*02, and/or do not express an HLA-A*02:01 allele.

### Claim 133 (depends on 132)

The method of claim 132, wherein the HCT comprises a donor hematopoieitic cell comprising a chromosomal knockout of a gene that encodes an HLA component, a chromosomal knockout of a gene that encodes a TCR component, or both.

### Claim 134 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any one of claims 92-133, wherein the subject had previously received lymphodepleting chemotherapy.

### Claim 135 (depends on 134)

The method of claim 134, wherein the lymphodepleting chemotherapy comprised cyclophosphamide, fludarabine, anti-thymocyte globulin, or a combination thereof.

### Claim 136 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The method of any one of claims 92-135, further comprising administering at least one additional treatment for the non-malignant disorder, the hyperproliferative disorder or the relapse of a hyperproliferative disorder to the subject.

### Claim 137 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The method of any one of claims 92-136, wherein the at least one additional treatment for the non-malignant disorder, the hyperproliferative disorder or the relapse of a hyperproliferative disorder is administered concurrently or sequentially with the composition.

### Claim 138 (depends on 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137)

The method of any one of claims 81-137, wherein the subject is an animal model of disorder characterized by HA-2 expression and/or a mammal, optionally wherein the mammal is a human, a primate, or a rodent.

### Claim 139

An expression vector comprising a promoter operably linked to a nucleic acid sequence encoding CD8α and/or CD8β.

### Claim 140 (depends on 139)

The vector of claim 139, wherein the nucleic acid sequence encoding CD8α or CD8β is operably linked to a nucleic acid encoding a tag such that the tag is fused to the CD8α or CD8β.

### Claim 141 (depends on 139, 140)

The vector of claim 139 or 140, wherein the nucleic acid encoding a tag is at the 5′ upstream of the nucleic acid sequence encoding CD8α or CD8β such that the tag is fused to the N-terminal of CD8α or CD8β.

### Claim 142 (depends on 139, 140, 141)

The vector of any one of claims 139-141, wherein the tag is a CD34 enrichment tag.

### Claim 143 (depends on 139, 140, 141, 142)

The vector of any one of claims 139-142, wherein the vector further comprises a nucleic sequence encoding a TCRα and/or TCRβ.

### Claim 144 (depends on 139, 140, 141, 142, 143)

The vector of any one of claims 139-143, wherein the TCRα and/or TCRβ comprises a mutated transmembrane domain and/or a mutated constant domain.

### Claim 145 (depends on 139, 140, 141, 142, 143, 144)

The vector of any one of claims 139-144, wherein the mutated transmembrane domain and/or mutated constant domain enhance cellular surface expression of TCRα and/or TCRβ while decreasing expression of endogenous TCRα and/or TCRβ.

### Claim 146 (depends on 139, 140, 141, 142, 143, 144, 145)

The vector of any one of claims 139-145, wherein the nucleic acid sequence encoding CD8α and/or CD8β and the nucleic sequence encoding TCRα and/TCRβ, are interconnected with an internal ribosome entry site or a nucleic acid sequence encoding a self-cleaving peptide.

### Claim 147 (depends on 139, 140, 141, 142, 143, 144, 145, 146)

The vector of any one of claims 139-146, wherein the self-cleaving peptide is β2A, E2A, F2A or T2A.

### Claim 148 (depends on 139, 140, 141, 142, 143, 144, 145, 146, 147)

The vector of any one of claims 139-147, wherein the vector further comprises a nucleic sequence encoding a polypeptide selected from the group consisting of polypeptide sequences listed in Table 1, or a sequence with at least about 80% homology to a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptide sequences listed in Table 1, optionally wherein the isolated nucleic acid molecule comprises 1) a TRAV, TRAJ, and/or TRAC gene or fragment thereof selected from the group of TRAV, TRAJ, and TRAC genes listed in Table 1 and/or 2) a TRBV, TRBJ, and/or TRBC gene or fragment thereof selected from the group of TRBV, TRBJ, and TRBC genes listed in Table 1.

### Claim 149 (depends on 139, 140, 141, 142, 143, 144, 145, 146, 147, 148)

The vector of any one of claims 139-148, wherein the vector has a nucleic sequence set forth in Table 2.
